Skip to main content

Home

Event Details

Compugen Participation at the TIGIT Axis Therapies Digital Summit

December 8, 2022 2:30 PM ET

Interview ahead of the summit with Eran Ophir, Ph.D., SVP, Research and Drug Discovery, Compugen (opens in new window)
Presentation (opens in new window)
Presentation Video (opens in new window)

Headquarters

Compugen Ltd.

Azrieli Center
26 Harokmim St., Bldg D
Holon 5885849, Israel

Investor Contact

Investor Relations
Telephone: +16282410071
Email: ir@cgen.com

Investor Email Alerts

Personal Information.

Your Email *Required Email Address is required. Email Address is invalid.

Mailing Lists *

Press Releases
End of Day Stock Quote
Events

Investor Alert Options is required.

The captcha test has failed. Please try again.

About

About Compugen opens in new window
Leadership opens in new window
Board of Directors opens in new window
Scientific and Strategic Advisory Board opens in new window
Contact Us opens in new window

Unigen™

Overview opens in new window

Pipeline

Overview opens in new window
COM701/COM902/Pembrolizumab Triple Combination opens in new window
COM902/high affinity Fc reduced anti-TIGIT antibody opens in new window
GS-0321 opens in new window
Discovery Programs opens in new window
RILVEGOSTOMIG/Fc reduced anti-PD1/TIGIT bispecific antibody opens in new window

Clinical Trials

MAIA-ovarian opens in new window
COM701/COM902/Pembrolizumab Triple Combination opens in new window
Rilvegostomig opens in new window
GS-0321 (previously COM503) opens in new window

Privacy Policy opens in new window
Terms of Use opens in new window
Accessibility Statement opens in new window
Site Map opens in new window

© 2026 Compugen Ltd - All rights reserved

Powered By Q4 Inc. 5.177.0.3 (opens in new window)